Autoinjector development expertise and capabilities

Elexy™ is a versatile, electromechanical autoinjector that features a reusable power unit compatible with drug cassettes containing a pre-filled syringe or a cartridge. Its versatility enables a wider choice of intended injection profiles, including drug volume, drug viscosity, and injection speed. In ...

The Molly® Connected Cap is a compact, retrofittable autoinjector add-on that records and transmits data on patients’ use of the device. Upon cap removal from the Molly device, the Connected Cap becomes active, allowing timestamped data to be relayed either through a smartphone app or smart data transmissi...

Molly is a single-dose autoinjector technology developed to help pharma and biotech companies reduce initial investments and expedite development timelines. Built on a proven modular platform, Molly reduces risks during the development process while increasing flexibility in device design and production. A...

Maggie® 5.0 is an innovative, large-volume, cartridge-based autoinjector built with SHL’s market-proven Needle Isolation Technology (NIT®). A two-step autoinjector, it was developed with a focus on opening a new pathway for handheld devices to accommodate a wider variety of formulation characteristics, suc...

Maggie is a cartridge-based autoinjector that accommodates fill volumes of up to 3.0 mL. Built with SHL’s market-proven Needle Isolation Technology (NIT®), this 2-step autoinjector uses a pre-attached and sterile needle housed within the device cap. The needle automatically attaches to the cartridge upon c...

NIT® is a safety solution that eliminates the need for manual needle attachment in cartridge-based injections. It enables cartridges to be built into autoinjectors, supporting treatments beyond the 2.25 mL fill range and lyophilized drugs requiring dual-chamber containers. 
Products built with NIT ...

InsulCheck DOSE by Innovation Zed is a reusable add-on device that automatically transfers injection time and dialed dose units to a mobile application. Built with a customizable sleeve and firmware over-the-air (FOTA) capability, InsulCheck dose can accommodate any pen injector and continuously imp...

VSDI+NIT is a cartridge-based autoinjector built with SHL’s Needle Isolation Technology (NIT®). NIT eliminates the need for patients to manually attach the needle before each injection. With cartridge compatibility ranging from 1.5 mL to 3.0 mL, this autoinjector’s dosing variations can be customized to cu...

SDI MIX+NIT is a dual-chamber disposable autoinjector built with SHL’s NIT (Needle Isolation Technology), which allows cartridge-based injectors to be built into easy-to-use autoinjectors. To accommodate drug formulations that need to be reconstituted prior to patient administration, the device features a ...

SHL Medical is pleased to announce the release of its 2023 sustainability report, which details the company’s ongoing efforts and accomplishments in sustainability and innovation. 

Ready to embark on a journey where connectivity meets autoinjectors? Dive into the world of SHL Medical’s Molly® Connected Cap and experience the future of healthcare. Driven by its experience with commercializing over three dozen autoinjectors worldwide, including 17 combination product projects from the market-proven Molly modular platform technology, SHL Medical developed the Molly Connected Cap autoinjector – an agile solution that supports remote adherence monitoring for personalized care.
Explore the webpage to learn how Molly Connected Cap can help transform patients’ treatment journey: https://bitly.ws/32ZBu

In this presentation, we introduce our most recent development – a versatile, reusable, and connected electromechanical solution that upholds the concept of drug agnosticism, platform flexibility, ease-of-use, as well as device programmability. By leveraging technological application expertise, we demonstrate how an electromechanical, versatile device platform can flexibly host different primary containers and formulations. Here, we also demonstrate how adding programmable firmware into the device circumvents formulation uncertainties across the pre-clinical, clinical, and commercial development of the drug counterpart. Finally, we show how the conserved element of the device results into an autoinjector solution that flexibly addresses various primary containers, therapy areas, regional healthcare landscapes, as well as patient groups. We also discuss an optional function for tracking injection-related data, opening pathways to gather detailed insights into the patient experience, and ultimately opening possibilities to connect such device usage data with other digital health solutions.

Abstract: Digital health solutions create myriad possibilities in terms of enabling “beyond the pill” health outcomes. However, the path to streamlining a strategic approach between pharma and its development partners toward creating smart combination products remains a challenge. With a general consensus that developers must accurately determine in advance what users want, many companies wait upon the success of early players as a determinant to foray into digital health. This philosophy, however, disregards the heterogeneity of combination products in development along with the diversity of clinical or patient-reported outcomes measures. Here, we present a dissection of SHL’s Innovation Partnership program along with our connected device offering – both of which allows us to flexibly collaborate with any pharmaceutical partner in the development of connected therapeutics.